PhaseBio Pharmaceuticals Accrued Expenses

Accrued Expenses of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accrued Expenses growth rates and interactive chart. Accrued expense is expense which has been incurred but not yet paid. Expense must be recorded in the accounting period in which it is incurred. Therefore, accrued expense must be recognized in the accounting period in which it occurs rather than in the following period in which it will be paid.

Highlights and Quick Summary

  • Accrued Expenses for the quarter ending September 29, 2021 was $6.12 Million (a -4.45% decrease compared to previous quarter)
  • Year-over-year quarterly Accrued Expenses increased by 3.24%
  • Annual Accrued Expenses for 2020 was $5.93 Million (a 86.51% increase from previous year)
  • Annual Accrued Expenses for 2019 was $3.18 Million (a 14.76% increase from previous year)
  • Annual Accrued Expenses for 2018 was $2.77 Million (a 116.32% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accrued Expenses of PhaseBio Pharmaceuticals

Most recent Accrued Expensesof PHAS including historical data for past 10 years.

Interactive Chart of Accrued Expenses of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Accrued Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $6.12 $6.41 $5.4
2020 $5.93 $3.91 $5.82 $1.89 $5.93
2019 $3.18 $2.31 $1.43 $1.32 $3.18
2018 $2.77 $2.99 $2.77
2017 $1.28

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.